Antibiotic resistance, biofilm formation, and biofilm-associated genes among Stenotrophomonas maltophilia clinical isolates by Bostanghadiri, N. et al.
Bostanghadiri et al. BMC Res Notes          (2021) 14:151  
https://doi.org/10.1186/s13104-021-05567-y
RESEARCH NOTE
Antibiotic resistance, biofilm 
formation, and biofilm-associated genes 
among Stenotrophomonas maltophilia clinical 
isolates
Narjess Bostanghadiri1, Abdollah Ardebili2,3, Zohreh Ghalavand4, Samane Teymouri1, Mahsa Mirzarazi5, 
Mehdi Goudarzi4, Ehsan Ghasemi6 and Ali Hashemi4*  
Abstract 
Objective: The purpose of the present study was to investigate the antimicrobial susceptibility pattern, biofilm pro-
duction, and the presence of biofilm genes among the S. maltophilia clinical isolates. A total of 85 clinical isolates of 
S. maltophilia were collected from patients referred to several hospitals. Susceptibility to antibiotics was investigated 
by disc diffusion method according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI). By the 
crystal violet staining method, the capability of biofilm formation was examined. The genes associated with biofilm 
production were investigated by the PCR-sequencing techniques.
Results: All isolates were resistant to doripenem, imipenem, and meropenem. Minocycline, trimethoprim/sulfameth-
oxazole and levofloxacin exhibited the highest susceptibility of 100%, 97.65%, and 95.29%, respectively. The results of 
crystal violet staining assay showed that all isolates (100%) form biofilm. Moreover, 24 (28.23%), 32 (37.65%), and 29 
(34.12%) of isolates were categorized as weak, moderate, and strong biofilm producers, respectively. Biofilm genes 
including rpfF, spgM and rmlA had an overall prevalence of 89.41% (76/85), 100% (85/85) and 84.71% (72/85), respec-
tively. Rational prescribing of antibiotics and implementation of infection control protocols are necessary to prevent 
further infection and development of antimicrobial resistance. Combination strategies based on the appropriate 
antibiotics along with anti-biofilm agents can also be selected to eliminate biofilm-associated infections.
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Introduction
Stenotrophomonas maltophilia, previously known as 
Pseudomonas maltophilia or Xanthomonas maltophilia, 
has become nowadays a major opportunistic patho-
gen in hospitalized or immunocompromised patients 
worldwide [1]. This organism is the most prevalent non-
fermenting Gram-negative bacilli in clinical laboratories 
after  P. aeruginosa  and Acinetobacter baumannii [2]. In 
addition, it is known to causes severe infections such as 
acute exacerbations of chronic obstructive pulmonary 
disease (COPD), pneumonia, bacteremia, sepsis, bone, 
and joint infections, eye infections, endocarditis, and 
meningitis [3, 4]. S. maltophilia  isolates show resistance 
to a variety of antibacterial agents, with various types of 
antimicrobial resistance mechanisms  [5–7], leading to a 
great challenge for physicians and clinical microbiolo-
gists to manage related infections [8, 9].
A prominent feature of S. maltophilia is its capabil-
ity to adhere to abiotic surfaces, host tissues and biofilm 
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formation [10, 11]. S. maltophilia has been identified on 
the surfaces of biomaterials used in prosthetic devices, 
intravenous cannula, dental unit waterlines and nebu-
lizers [12–14]. The biofilm-forming capacity of S. malt-
ophilia has increasingly been accepted as an important 
virulence factor and is thought to play a significant role 
in the persistence of S. maltophilia infections in hospital 
settings [10, 15–19] The molecular mechanisms of bio-
film formation in S. maltophilia is poorly investigated 
[18, 19]. Several genes are associated with biofilm-forma-
tion. The spgM gene encodes a bifunctional enzyme with 
both phosphoglucomutase and phosphomannomutase 
activities that is involved in LPS biosynthesis, playing an 
important role in biofilm formation [18, 20]. Mutation in 
spgM gene, may cause fewer LPS production and shorter 
O polysaccharide chains [21]. The rmlA gene encodes 
glucose-1-phosphate thymidyltransferas that is involved 
in LPS/EPS-coupled biosynthetic pathway It is reported 
that mutations in  rmlA and  rpfF  genes resulted in 
reduced biofilm formation in S. maltophilia [4, 19]. The 
rpfF gene, encoding the DSF (diffusible signal factor) syn-
thase regulates the virulence expression, such as motil-
ity, extracellular proteases, LPS, and biofilm production. 
RpfF protein has some amino acid sequences similar to 
enoyl coenzyme A hydratases [19].
Considering the potential of biofilm in increasing anti-
microbial resistance and subsequently, the increased 
rates of chronic infections caused by S. maltophilia, iden-
tification of the isolates with such factor will be benefit to 
better understand the pathogenesis of the organism. The 
aim of this survey was to investigate the pattern of antibi-
otic susceptibility, the ability of biofilm production, and 




Bacterial isolates and species identification
S. maltophilia isolates included in this study were origi-
nated from different clinical samples of patients admitted 
at selected hospitals in Tehran, Iran from January 2018 to 
January 2019. All of the isolates were identified by stand-
ard microbiological and biochemical methods, including 
catalase and oxidase tests, reactions in media, such as 
triple sugar iron agar, deoxyribonuclease test agar, and 
SIM (Merck company, Germany). S. maltophilia isolates 
were then confirmed by the PCR amplification of the 
16S rRNA gene and sequencing (Table  1). All isolates 
were stored in Luria–Bertani (LB) liquid medium (Merck 
company-Germany) containing 15% glycerol at − 80  °C. 
Escherichia coli ATCC 25,922 and S. maltophilia ATCC 
13,637 were used as the quality control strains.
Antimicrobial susceptibility testing
The antibiotic sensitivity pattern of S. maltophilia isolates 
was evaluated by the Kirby-Bauer disc diffusion method 
as described by the Clinical and Laboratory Standards 
Institute (CLSI) [22]. Antibiotic discs used for suscep-
tibility testing were levofloxacin (5  μg), minocycline 
(30  μg), imipenem (10  μg), meropenem (10  μg), dorip-
enem (10  μg), sulfamethoxazole/trimethoprim (SMX/
TMP) (1.25/23.75  μg), tetracycline (30  μg), and ceftazi-
dime (30  μg) (MAST Diagnostics, Merseyside, UK). 
Control strains of E. coli ATCC 25922 and E. coli ATCC 
35218 were used for susceptibility testing.
DNA preparation
S. maltophilia isolates were cultivated on Columbia agar 
medium (bioMérieux Italia S.p.A-Italy) supplemented 
with 5% sheep blood and incubated at 37 °C for 24 h. The 
DNA samples were extracted from the grown colonies of 
each isolate with high pure PCR Template Preparation 
Kit (Roche company-Germany). The total DNA concen-
tration was evaluated by Nanodrop (WPA Biowave II 
Nanospectrophotometer-USA).
PCR‑sequencing techniques
The presence of biofilm-encoding genes, including rpfF, 
spgM, and rmlA was investigated in S. maltophilia isolates 
by PCR technique using the specific primers (Table  1). 
PCRs were performed on a thermal cycler (Eppendorf, 
Master Cycler Gradient- Germany) in 25-μl reaction vol-
umes with 1 μl (20 ng) of DNA template, 1 × PCR buffer, 
12.5  μl of 2 × Master Mix (SinaClon-Iran), 3  mmol/L 
 MgCl2, 0.4  mmol/L dNTPs, 9.5  μl of sterile distilled 
water, 1 μl of 10 pmol of each primer, and 0.08 IU of Taq 
DNA polymerase. PCR conditions were under the follow-
ing: denaturation at 95 °C for 10 min, and then 36 cycles 
at 94 °C for 60 s, annealing at 52–60 °C, depending to the 
primers for each gene, for 60 s, and extension at 72 °C for 
60 s, followed by a final extension at 72 °C for 5 min. PCR 
Table 1 Oligonucleotide primers used in this study
Genes Sequences (5’→3’) Target References
16srRNA-F AGT TCG CAT CGT TTA GGG 16 s RNA [2]
16srRNA-R ACG GCA GCA CAG AAG AGC 
spgM-F ATA CCG GGG TGC GTT GAC spgM [18]
spgM-R CAT CTG CAT GTG GAT CTC GT
rpfF-F CAC GAC AGT ACA GGG GAC C rpfF [18]
rpfF-R GGC AGG AAT GCG TTGG 
rmlA-F CGG AAA AGC AGA ACA TCG rmlA [3]
rmlA-R GCA ACT TGG TTT CAA TCA CTT 
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products were electrophoresed by 1.2–1.5% agarose gel, 
visualized by DNA Safe staining, and then photographed 
under UV light.
The amplicons were purified using a PCR purification 
Kit (BioFact Co., South Korea), and then sequenced by 
an ABI PRISM 3700 sequencer (Applied Biosystems Inc., 
USA). The nucleotide sequences were analyzed using 
FinchTV software and comparisons were made using the 
NCBI BLAST program (http:// www. ncbi. nlm. nih. gov/ 
BLAST/).
Biofilm formation assay
Biofilm formation by S. maltophilia was evaluated using 
crystal violet staining method as previously described by 
Stepanović et al. [23]. All experiments were run in trip-
licate. An overnight culture of isolates was adjusted to 
the turbidity of a 1.0 McFarland standard. Suspensions 
were diluted at a ratio of 1:100 in 200 ml tryptic soy broth 
(TSB) (Merck, Darmstadt- Germany) containing 1% glu-
cose and, were dispensed to the sterile flat-bottomed 
96- well polystyrene microplates (JET Biofil, Guangzhou, 
China). After 24  h of incubation at 37  °C, microplates 
were washed three times with sterile phosphate-buffered 
saline (PBS, pH 7.3). Adherent biofilms were fixed for 1 h 
at 60  °C, stained by 200 µl Hucker modified crystal vio-
let (Sigma Chemical Company- USA) for 5 min at room 
temperature and then rinsed with water and allowed to 
dry. Biofilm samples were destained with 200  ml 33% 
glacial acetic acid for 15  min. The optical density (OD) 
was measured at 492 nm using a microtiter plate reader 
(BioTek, Bad Friedrichshall, Germany). A cut-off value 
(ODc) was established. It is defined as three standard 
deviations (SD) above the mean OD of the negative con-
trol: ODc = average OD of negative control + (3 × SD 
of negative control). The isolates were categorized into 
four groups according to the following criteria: non-
biofilm producer (OD < ODc), weak-biofilm producer 
(ODc < OD < _2 × ODc), moderate-biofilm producer 
(2 × ODc < OD < 4 × ODc), and strong-biofilm producer 
(4 × ODc < OD).
Statistical analysis
The statistical analysis of data was performed with statis-
tical software SPSS, 20.0 (SPSS Inc., Chicago, IL, USA). 
Chi-squared test was used to determine the association 




During one-year period, 85 S. maltophilia isolates were 
gathered from several health centers in Tehran, Iran. 
Among them, 49 isolates were from males and 36 isolates 
from females (male: female ratio = 1.36). Most of the S. 
maltophilia (90.03%) were isolated from the blood, while 
the rest (9.97%) were from the cough swabs. The range of 
patients’ age was from 2 months to 85 years.
Antimicrobial susceptibility
The results of susceptibility testing on planktonic cells 
showed that approximately 100%, 96%, 96%, 36.58%, 
2.35% of the S. maltophilia  isolates were resistant to 
imipenem, doripenem, meropenem, ceftazidime and 
SMX/TMP-, respectively. Levofloxacin and minocycline 
(95.29% and 100% susceptibile, respectively) exhibited 
the highest activity against S. maltophilia, with a rate of 
(Table 2).
Biofilm formation
In this study, the biofilm forming ability was assessed on 
polystyrene using the microtiter plate method. Biofilm 
phenotypes accounted for 100%, being distributed as fol-
low: 24 isolates (28.23%) produced weak biofilm, 32 iso-
lates (37.65%) produced moderate biofilm, and 29 isolates 
(34.12%) produced strong biofilm.
Biofilm‑encoding genes
The frequency of biofilm-related genes among the  S. 
maltophilia isolates was generally as high as 89.41%, 
100%, and 84.71% for rmlA,  spgM and  rpfF  genes, 
respectively (Fig.  1). Among them, 63 isolates car-
ried all three genes studied. S. maltophilia  isolates 
with  spgM + /rpfF + /rmlA + genotype showed strong or 
moderate biofilm-producer phenotype.
Discussion
S. maltophilia is increasingly identified as a cause of 
nosocomial infections, especially among immunosup-
pressed patients [24]. Treatment of infections caused 
by this pathogen is a problem for clinicians because of 
Table 2 Antibiotic susceptibility of S. maltophilia clinical isolates 
(n = 85)
Antimicrobial agents Antimicrobial susceptibility pattern, n 
(%)
Susceptible Intermediate Resistant
Imipenem – – 85 (100%)
Meropenem – – 85 (100%)
Doripenem – – 85 (100%)
Ceftazidime 24 (28.24%) – 61 (75.72%)
Minocycline 85 (100%) – –
Levofloxacin 81 (95.29%) – 4 (4.71%)
Sulfamethoxazole/trimetho-
prim
83 (97.65%) – 2 (2.35%)
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its resistance to a broad array of antimicrobial drugs 
[25]. In the present study, all isolates were resist-
ant to carbapenems (p ≤ 0.001). Similarly, a previous 
study showed that resistance rates to imipenem and 
meropenem in S. maltophilia were 100% and 92.4%, 
respectively [26]. Moreover, our results showed a sus-
ceptibility rate of 28.24% to ceftazidime. A study by 
Farrell et al. showed that susceptibility of S. maltophilia 
against ceftazidime was 32.51% in Latin America, 
North America, Asian-Pacific, and Europe [26]. In con-
trast, Jamali et al. reported the susceptibility rate of 82% 
against this drug [27]. In our study, 100% and 95.29% of 
S. maltophilia were susceptible to minocycline and lev-
ofloxacin, respectively. Duan et al. showed also the sus-
ceptibility rates of 100% and 95.7% to minocycline and 
levofloxacin, respectively [28]. These findings indicate 
that such antibiotics serve as effective agents for treat-
ment of S. maltophilia infections. On the other hand, 
the most effective antimicrobial agent used to treat  S. 
maltophilia infections is SMX/TMP [29]. In a study by 
Jamali et al., 5% of isolates were resistant to SMX/TMP 
[30]. The susceptibility rates were reported as high 
as 95% in several studies conducted in most regions, 
including Latin America, North America, Europe [30–
32]. In our study, 97.65% of isolates were found to be 
susceptible to SMX/TMP, indicating this antibiotic has 
increasingly become the last resort drug for the treat-
ment of multi-resistant S. maltophilia infections. How-
ever, the highest rates of resistance have been reported 
in isolates obtained from patients in Asian countries, 
such as Malaysia, Korea, and Taiwan [33]. The pre-
sent study generally reveals a low frequency of anti-
biotic resistance among the S. maltophilia. However, 
monitoring of the antibiotic resistance trends is nesser-
ary either geographically or over time.
All S. maltophilia isolates tested in this study were 
able to produce biofilms. In a study by Flores-Trevino 
et al., isolates were categorized as weak- (47.9%), moder-
ate- (38.7%), or strong- (13.4%) biofilm producers [34]. 
In contrast, Gallo et al. showed that isolates were biofilm 
producers as weak (3%), moderate (45%), or strong (48%) 
[35]. From 2016 to 2017 in Iran, 47.9, 38.7, and 13.4% 
of out of 164 S. maltophilia clinical isolates were weak-, 
moderate-, and strong-biofilm producers, respectively 
[36].
Biofilms have been recognized to be involved in many 
chronic and intractable infections [13, 37]. The results of 
this study showed biofilm formation significantly corre-
lated with ceftazidime and SMX/TMP resistance. Simi-
larly, biofilm formation has been shown associated with 
resistance to different antibiotics, including ceftazidime, 
piperacillin/tazobactam, cefepime, ticacillin/clavulanic 
acid, aztreonam, and gentamicin [38]. more understand-
ing of biofilm dynamics can lead to development of a 
effective treatment, and control, strategies for eradication 
of infections, improving patient care [39].
In the present study, we investigated the relation-
ship between biofilm formation and the presence of its 
related genes rpfF, spgM, and rmlA. Sixty-three isolates 
of S. maltophilia strains had all genes studied, while 
only 81 strains carried the spgM. Overall, our results 
revealed that the presence of the spgM significantly 
promoted biofilm formation, in accordance to those 
obtained by Pompilio et al. [40]. In a study by Zhongli-
ang Duan et al. the rates of spgM, rmlA, and rpfF bio-
film genes were 100%, 83.7%, and 45.2%, respectively 
Fig. 1 The amplification of biofilm-encoding genes in S. maltophilia isolates. L: 100 bp DNA ladder, P: positive control, N: negative control, Lanes 1 
to 7: PCR products of the corresponding genes: a; rmlA gene, b; rpfF gene,  c; spgM gene
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[17]. Zhuo et  al. indicated that biofilm formation was 
considerably associated with the presence of rpfF and 
spgM genes [18]. Moreover, the presence of either rpfF 
or spgM was significantly correlated to biofilm produc-
tion, although the strongest biofilm was formed when 
both genes were present [15]. The presence of spgM, 
rpfF, and rmlA genes improved significantly the biofilm 
production in our isolates.
In conclusion, although the rate of resistance to multi-
ple antibiotics among our S. maltophilia isolates was rel-
atively low, cautious antimicrobial use and high standards 
of infection prevention and control are needed to prevent 
further development of resistant isolates. Additionally, 
combination strategies based on the proper antibiotics 
with anti-biofilm agents can be used to improve the treat-
ment of biofilm-associated infections.
Limitations
A limitation of this study may be the lack of evalua-
tion of expression levels of biofilm-associated genes by 
quantitative real-time PCR, an approach that may help 
to assess the role of each corresponding gene in biofilm 
production.
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